Valuation: Jade Biosciences, Inc.

Market Cap 1.36B 1.16B 1.09B 996M 1.87B 130B 1.89B 12.85B 5.01B 65.23B 5.1B 4.99B 216B P/E 2026 *
-7.38x
P/E 2027 * -7.44x
Enterprise Value 1.01B 866M 811M 742M 1.39B 96.78B 1.41B 9.58B 3.74B 48.62B 3.8B 3.72B 161B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day+0.52%
1 week-13.64%
Current month+8.05%
1 month+7.51%
3 months-3.92%
6 months+49.54%
Current year+38.30%
1 week 20.7
Extreme 20.7
24.94
1 month 18.54
Extreme 18.54
25
Current year 12.45
Extreme 12.45
28
1 year 6.91
Extreme 6.91
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/6/26 Free

Director

47,675 0.0966%
12/2/26 Free

General Counsel

196,875 0.4280%
12/2/26 Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%-13.64%+159.30% - 1.36B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.45%+2.63%+91.57%+126.32% 27.78B
Weighted average by Cap. +0.49%+4.63%+99.88%+146.30%

Financials

2026 *2027 *
Net sales - -
Net income -204M -175M -164M -150M -281M -19.54B -285M -1.93B -754M -9.82B -767M -750M -32.47B -231M -198M -185M -170M -318M -22.11B -322M -2.19B -854M -11.11B -868M -849M -36.75B
Net Debt -346M -296M -277M -254M -476M -33.07B -482M -3.27B -1.28B -16.61B -1.3B -1.27B -54.96B -354M -303M -283M -260M -487M -33.84B -493M -3.35B -1.31B -17B -1.33B -1.3B -56.23B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
21/08/26 US$21.34 +0.52% 571,848
20/08/26 US$21.23 -5.85% 936,622
19/08/26 US$22.55 -4.25% 789,060
18/08/26 US$23.55 +0.43% 721,657
17/08/26 US$23.45 -5.10% 671,571
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.34USD
Average target price
50.12USD
Spread / Average Target
+134.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock